Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
9 years ago
Gilead bags Sarepta's priority review voucher for a discount, paying $125M
9 years ago
An FDA reform agenda: What would Commissioner Scott Gottlieb do in his first six months?
9 years ago
After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version
9 years ago
Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well
9 years ago
In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS
9 years ago
R&D
Alexion shelves an early-stage Sanfilippo B drug, writes off $85M
9 years ago
PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy
9 years ago
People
Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch
9 years ago
Patent board tells CRISPR scientists to back off from a nasty fight over gene editing tech
9 years ago
The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
9 years ago
People
Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte
9 years ago
R&D
Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price
9 years ago
Activists slam Immunomedics’ $2B deal with Seattle Genetics in the middle of a proxy war
9 years ago
The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price
9 years ago
Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK
9 years ago
R&D
Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal
9 years ago
R&D
Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K
9 years ago
Sanofi, Regeneron win a crucial stay of execution on Praluent
9 years ago
After clearing an FDA hurdle, Amgen wins an FDA OK on CKD drug Parsabiv
9 years ago
Two friends and biotech colleagues with a passion for insider info - feds charge Merrimack staffer
9 years ago
As hep C revenue disintegrates, pressure keeps growing on Gilead to do deals
9 years ago
White House: Trump remains committed to Medicare drug price negotiations
9 years ago
A swarm of top biotech execs protest against Trump’s travel ban, saying it threatens the entire industry
9 years ago
People
First page
Previous page
333
334
335
336
337
338
339
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit